Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
At the request of Monsigneur André Mulch, Archbishop of Rouen, Pope Paul VI decided on 6 July 1974 through the papal bull Quae Sacrosanctum on the creation of the diocese of Le Havre (Portus Gratiae in Latin meaning "Port of Grace"). The diocese was created from part of the parishes of the Archdiocese of Rouen to the west of a line joining Norville to Sassetot-le-Mauconduit. Monseigneur Michel Saudreau, its first bishop, was ordained on 22 September 1974. The church of Notre Dame was promoted to Cathedral Notre Dame du Havre. Today, the commune of Le Havre is divided into eight parishes and 24 places of worship (churches and chapels). The oldest chapel is Saint-Michel d'Ingouville which dates back to the 11th century. The Church of Saint Joseph du Havre, built by Auguste Perret, dominates the city with its spire 107m high. There are several monastic establishments (Carmel of the Transfiguration, Franciscan Monastery, Little Sisters of the Poor, etc.). The Protestant Church of Le Havre was built in the city centre in 1862. Bombed in 1941, it lost its pediment, its bell tower, and roof. Rebuilt in 1953 by the architects Jacques Lamy and Gérard Dupasquier, who worked in the Auguste Perret office, is the only building in Le Havre uniting the original architecture of the 19th century with the architecture of the Perret school. Le Havre also has seven evangelical Protestant churches: Salvation Army, Seventh Day Adventist, Apostolic Church, Assembly of God, Baptist Church, Good News Church, et Church of Le Havre as well as several Protestant churches of African origin.
After several years of researching disgust, Jonathan Haidt, and others, studied its opposite; the term "elevation" was coined. Elevation is a pleasant moral emotion, triggered by witnessing virtuous acts of remarkable moral goodness and resulting in a desire to act morally and do "good". As an emotion it has a biological basis, and is sometimes characterized by a feeling of expansion in the chest or a tingling feeling on the skin.
== Signs and symptoms == Children with sJIA are frequently severely unwell when diagnosed. They often have lost weight and are tired, feverish, experiencing myalgia and arthralgia, as well as occasional chest and stomach pain. These characteristics may overshadow the arthritis in the early stages of the disease. The presence of fever at presentation is practically universal in those with sJIA. The distinctive fever pattern associated with sJIA is characterized by temperatures that surge above 39 °C once or twice a day and then quickly fall to normal or below baseline. More than 80% of patients have a salmon-colored macular or maculopapular rash that appears along with their fever. Urticarial rash is less prevalent. The eruption is usually limited to the trunk, neck, and proximal extremities, but it might spread more widely. Macules typically measure less than 5 mm in diameter, while bigger macules may be present with center fading. The degree of erythema varies in the same patient, however, it is usually migratory and nonpruritic. The existence of arthritis must be validated before meeting the diagnostic criteria. Although arthralgias are often present at onset, arthritis may not be visible at first and can develop weeks, months, or even years later. Additionally, there is a wide range of joint involvement, from polyarticular patterns to oligoarticular patterns (four or fewer joints with arthritis). The wrists, knees, and ankles are the joints that are most frequently affected.
Center for the Advancement of Science in Space—operates the US National Laboratory on the ISS Dielectric wall accelerator Lawrence Berkeley National Laboratory List of US DOE National Laboratories Top 100 US Federal Contractors
Berg did not complete his final step due to the pleas of several fellow investigators, including Robert Pollack, who feared the biohazards associated with the last step. The SV40 was known to cause cancer tumors to develop in mice. Additionally, the E. coli bacterium (although not the strain used by Berg) inhabited the human intestinal tract. For these reasons, the other investigators feared that the final step would create cloned SV40 DNA that might escape into the environment and infect laboratory workers. These workers could then become cancer victims. Concern about this potential biohazard, along with others, caused a group of leading researchers to send a letter to the president of the National Academy of Sciences (NAS). In this letter, they requested that he appoint an ad hoc committee to study the bio-safety ramifications of this new technology. This committee, called the Committee on Recombinant DNA molecules of the National Academy of Science, U.S.A., held in 1974, concluded that an international conference was necessary to resolve the issue and that until that time, scientists should halt experiments involving recombinant DNA technology.
Sources: en.wikipedia.org
Bohrium is a synthetic chemical element; it has symbol Bh and atomic number 107. It is named after Danish physicist Niels Bohr. As a synthetic element, it can be created in particle accelerators but is not found in nature. All known isotopes of bohrium are highly radioactive; the most stable known isotope is 270Bh with a half-life of approximately 2.4 minutes, though the unconfirmed 278Bh may have a longer half-life of about 11.5 minutes. In the periodic table, it is a transactinide element in the d-block. It is a member of the 7th period and belongs to the group 7 elements as the fifth member of the 6d series of transition metals. Chemistry experiments have confirmed that bohrium behaves as the heavier homologue to rhenium in group 7. The chemical properties of bohrium are characterized only partly, but they compare well with the chemistry of the other group 7 elements.
Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of diabetes mellitus. It contains insulin degludec and insulin aspart. It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh. The most frequently reported side effect is hypoglycemia (low blood glucose levels). It was approved for medical use in the European Union in January 2013, and in Australia in November 2017.
== Clinical significance == PAT1 mRNA is expressed in the GI tract between the stomach and descending colon, but is generally absent in the esophagus, caecum, and rectum. This allows for different treatments that affect the affinity of the carrier protein for its substrates, giving the potential to treat various amino-acid related diseases. HPAT1 and HPAT2 are important in the absorption of certain drugs, especially pharmaceutically active amino acids derivatives. They have also been targeted with medications used as anticonvulsants, for prostate cancer, and for bladder cancer. HPAT1 and 2 are integral to the central nervous system because they transport GABA and its analogues which can induce and inhibitory and excitatory effect in the brain.
"32 Battalion – The Terrible Ones". Accounts of both sides: A South African Soldier and an MK operative at the Wayback Machine (archived 27 October 2009) "South African Roll of Honour". Archived from the original on 11 April 2010. Retrieved 3 September 2014. "Sentinel Projects". "SA-Soldier Website". Archived from the original on 19 December 2011.
oxidative phosphorylation Also electron transport-linked phosphorylation or terminal oxidation. The process by which cells use chemical energy obtained by the oxidation of nutrients to power the production of adenosine triphosphate (ATP). Oxidative phosphorylation couples two related processes: in the electron transport chain, a series of enzyme-catalyzed redox reactions transfers electrons from energetic donors such as NADH and FADH through various intermediates and ultimately to a terminal electron acceptor such as molecular oxygen (O2); the energy liberated by these reactions is simultaneously used in chemiosmosis to move protons (H+) across a membrane and against their concentration gradient, generating an electrochemical potential which powers ATP synthase, an enzyme that catalyzes the phosphorylation of ADP into ATP. In eukaryotes, both of these processes are carried out by proteins embedded in the membranes of mitochondria and chloroplasts; in prokaryotes, they occur in the cell membrane.
Sources: en.wikipedia.org
== History == Flupirtine was discovered and developed between the 1970s and the 1990s by Chemiewerk Homburg in Frankfurt am Main, Germany, which became Degussa Pharma Group and then through mergers, ASTA Pharma and Asta Medica. Retigabine, a bioisostere of flupirtine, was discovered as part of the same program and has a similar mechanism of action. Flupirtine was approved for the treatment of pain in 1984 in Europe under the brand name Katadolon. As of 2013 it was used in 11 member countries: Bulgaria, Estonia, Germany, Hungary, Italy, Latvia, Lithuania, Poland, Portugal, Romania and Slovak Republic. Many generics entered the European market around 2011. It was never introduced to the United States market for any indication but in 2008, Adeona Pharmaceuticals, Inc. (now called Synthetic Biologics, Inc.) obtained an option to license issued and patent pending applications relating to flupirtine's use in the treatment of ophthalmic indications, particularly retinitis pigmentosa. As of 2016 it is marketed under many brand names, including Efiret, Flupigil, Flupirtin, Flupirtina, Flupirtine, Flupizen, Fluproxy, Katadolon, Metanor, Trancolong, and Zentiva.
Russia launched 16 missiles and 13 drones at energy infrastructure across Ukraine. Two energy workers in Zaporizhzhia Oblast were wounded. In Lviv Oblast a missile hit an energy facility, starting a fire. In Ivano-Frankivsk one of the buildings of Ivano-Frankivsk National Technical University of Oil and Gas was semi-destroyed and a kindergarten was damaged. Explosions were reported in Volyn and Vinnytsia Oblasts. Twelve missiles and all drones were shot down, according to the Ukrainian Air Force. Russian media reported that a Pantsir S-1 anti-aircraft missile system was struck in a Ukrainian air attack in Belgorod Oblast. Three people were killed in Russian airstrikes in Kharkiv.
Per CLIA, each specific laboratory system, assay, examination is graded for level of complexity by assigning scores of 1, 2, or 3 for each of the following seven criteria. A score of 1 is the lowest level of complexity, and a score of 3 is the highest. Score 2 is assigned when the characteristics for a particular test are intermediate between the descriptions listed for scores of 1 and 3. Criteria for categorization:
== Mechanism of action == The sensitization of pronociceptive pathways in response to opioid treatment appears to involve several pathways. Research thus far has primarily implicated the μ-opioid receptors (MOR) abnormal activation of NMDA receptors in the central nervous system, and long-term potentiation of synapses between nociceptive C fibers and neurons in the spinal dorsal horn.
=== Beginning === Most early progress in tissue engineering research was done in the US. This is due to less strict regulations regarding stem cell research and more available funding than in other countries. This leads to the creation of academic startups many of them coming from Harvard or MIT. Examples are BioHybrid Technologies whose founder, Bill Chick, went to Harvard Medical School and focused on the creation of artificial pancreas. Another example would be Organogenesis Inc. whose founder went to MIT and worked on skin engineering products. Other companies with links to the MIT are TEI Biosciences, Therics and Guilford Pharmaceuticals. The renewed interest in biotechnologies in the 1980s leads to many private investors investing in these new technologies even though the business models of these early startups were often not very clear and did not present a path to long term profitability. Government sponsors were more restrained in their funding as tissue engineering was considered a high-risk investment. In the UK the market got off to a slower start even though the regulations on stem cell research were not strict as well. This is mainly due to more investors being less willing to invest in these new technologies which were considered to be high-risk investments. Another problem faced by British companies was getting the NHS to pay for their products. This especially because the NHS runs a cost-effectiveness analysis on all supported products. Novel technologies often do not do well in this respect. In Japan, the regulatory situation was quite different.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.